论文部分内容阅读
目的评价细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)免疫治疗联合化疗治疗术后非小细胞肺癌(NSCLC)患者的近期疗效。方法选取82例Ib-IIIa期NSCLC患者,经手术治疗后随机分为两组,常规化疗组和CIK细胞治疗联合化疗组,每组41例。观察比较两组患者生活质量及外周血CD3+,CD4+,CD4+/CD8+比值,自然杀伤细胞(Na-ture-Kille)r比率以及Th1/Th2细胞因子水平免疫功能指标的变化。结果生活质量:CIK细胞治疗联合化疗组和常规化疗组生活质量总提高率分别为90.0%与73.2%,研究组患者生活质量高于对照组(P<0.05)。免疫功能指标:CIK细胞治疗联合化疗组于CIK细胞治疗后2周,外周血CD3+,CD4+T细胞,NK细胞和CD4+/CD8+的比值、白细胞介素-2,干扰素γ水平较治疗前升高(P<0.01),于治疗后4周达高峰,此后逐渐回落;而Th2细胞因子于CIK细胞治疗后2周下降,治疗后4周降至低谷。CIK细胞治疗联合化疗组于CIK细胞治疗后2、4、8周CD3+,CD4+,CD4+/CD8+,NK细胞,IL-2,IFN-γ,白细胞介素-4和白细胞介素-10与常规治疗组各时点比较差异有统计学意义(P<0.05)。结论 CIK细胞免疫治疗联合化疗能增强NSCLC患者术后的免疫功能,改善其生活质量。
Objective To evaluate the short-term effect of cytokine-induced killer (CIK) immunotherapy combined with chemotherapy in the treatment of postoperative non-small cell lung cancer (NSCLC). Methods Eighty-two patients with stage Ib-IIIa NSCLC were selected and randomly divided into two groups. The patients in the conventional chemotherapy group and the CIK cell group received 41 cases of chemotherapy. The quality of life and the ratio of CD3 +, CD4 +, CD4 + / CD8 +, Na-ture-Kille ratio and immune function of Th1 / Th2 cytokines in peripheral blood were compared between the two groups. Results Quality of Life: The total quality of life of CIK cells treated with chemotherapy and conventional chemotherapy were 90.0% and 73.2% respectively, and the quality of life of the study group was higher than that of the control group (P <0.05). Immune function indexes: The ratio of CD3 +, CD4 + T cells, NK cells and CD4 + / CD8 +, interleukin-2 and interferon-γ in peripheral blood of CIK cell treated with chemotherapy group were significantly higher than those before treatment (P <0.01), reaching the peak at 4 weeks after treatment, and then gradually decreased. Th2 cytokines decreased after 2 weeks of CIK cells treatment and dropped to the bottom 4 weeks after treatment. CIK cells combined with chemotherapy in CIK cells at 2, 4, 8 weeks after treatment CD3 +, CD4 +, CD4 + / CD8 +, NK cells, IL-2, IFN- γ, interleukin-4 and interleukin -10 and conventional treatment There was significant difference between groups at each time point (P <0.05). Conclusion CIK cell immunotherapy combined with chemotherapy can enhance the immune function of patients with NSCLC and improve their quality of life.